Isis Highlights Robust Drug Portfolio for Diabetes and Obesity at ADA ... (

Isis Highlights Robust Drug Portfolio for Diabetes and Obesity at ADA Conference

Date:6/10/2008

- Oral presentation on the potent blood glucose lowering effect of SGLT2

antisense inhibitors in multiple preclinical models - Eight additional presentations highlight significant activity in eight

new metabolic disease targets utilizing antisense

SAN FRANCISCO and CARLSBAD, Calif., June 10 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today the presentation of new preclinical data showing that antisense drugs potently reduce levels of sodium dependent glucose transporter type 2 (SGLT2), a key component in controlling glucose re-absorption in the kidney and the target of ISIS 388626. In addition, Isis presented results from eight research programs on novel targets that offer new mechanisms to treat metabolic diseases. The nine presentations (including two late-breaking abstracts) were presented during the American Diabetes Association's (ADA) 68th Scientific Sessions in San Francisco by Isis and its collaborators.

"These data provide further evidence of the power of Isis' antisense technology to discover and develop highly potent and specific molecules targeted against many novel targets to treat a broad spectrum of metabolic diseases," said Robert R. Henry, M.D., Professor of Medicine, University of California at San Diego, and Chief, Section of Diabetes, Endocrinology, and Metabolism at VA San Diego Healthcare System.

The presentation titled "Long Term Safety and Efficacy of ISIS 388626, an Optimized SGLT2 Antisense Inhibitor, in Multiple Diabetic and Euglycemic Species," showed that antisense reduction of SGLT2 produced the following results in preclinical models:

-- Lowered HbA1c, a measure of average blood glucose over time in

d
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Uroplasty Highlights Clinical Results From a Study of the Urgent(R) PC Neuromodulation System
2. Memory Pharmaceuticals Highlights Progress with Key Programs at its R&D Day
3. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
4. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
5. Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
6. Sarasotas Roskamp Institute Highlights Positive Japanese Data that Validates its Ongoing Alzheimers Disease Research
7. Research Highlights Potential Benefits of Telemedicine in Treating Eye Disease
8. Synvista Therapeutics Highlights New Data Demonstrating the Clinical Benefit of Vitamin E Therapy in Patients Identified on the Basis of Haptoglobin Phenotype Testing
9. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
10. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
11. President Clinton Highlights MWW Group at the 2007 Clinton Global Initiative for its Stop Neglected Tropical Disease Campaign

Post Your Comments:

(Date:10/6/2008)...October 7 /-,Sosei Group Co...ectura,Group plc ("Vectura"; LSE: VEC), announce r...cacy, safety and tolerability of NVA237 presented ... Society (ERS) in Berlin,Germany. The new data sh...nhaled long-acting muscarinic antagonist (LAMA), p...

(Date:10/6/2008)...wswire/ -- "A return to the use of,chimpanzees in ...cientific,justification," according to a paper rel...ory Animals (ATLA). "An Assessment of the Role of,...at vaccine responses in,chimpanzees are not predic...impanzees, critical role and importance in AIDS va...

(Date:10/6/2008)... children, parents discussing clinical ...6 /PRNewswire-USNewswire/ -- From asthma and cance...es lives and improves their,health and well-being....alth (NIH), "Children and Clinical Studies", (http... offers parents and health,care providers an insid...

(Date:10/6/2008)...with Durezol Dosed Prior to Surgery, TAMPA, Fla.,... a,privately held ophthalmic-focused biopharmaceut...fluprednate ophthalmic emulsion) 0.05% is now,comm... the U.S. Food and,Drug Administration in June 200...d for the treatment of inflammation and pain assoc...

[0] NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium [0] Research Attributes Lack of HIV/AIDS Vaccine to Use of Chimpanzees [0] Photos: NIH Launches New Web Site for Parents on Medical Research Studies for Children [0] Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain

...WIRE)--Jul 2, 2007 - ViaCell, Inc.,(NASDAQ: VIAC) ...hief Executive Officer of ViaCell, will present an...eline at the C.E. Unterberg,Towbin Emerging Growt...07 at 3:00 p.m. at the Mandarin Oriental Hotel in ...tion will be available on,the Investor Information...

..., July 10, 2007 /CNW/ - Protox,Therapeutics Inc. (...lts from its Phase 1 clinical trial evaluating ,PR...e cancer,following radiation failure. The trial r...rated and shows promising signs,of therapeutic act...t. , ,"The completion of the PRX302 Phase 1 ...

Other Medicine Technology:Protox Announces Positive Clinical Data from Prostate Cancer Study 2 Protox Announces Positive Clinical Data from Prostate Cancer Study 3 Protox Announces Positive Clinical Data from Prostate Cancer Study 4 Protox Announces Positive Clinical Data from Prostate Cancer Study 5

ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth,Opportunities Conference Protox Announces Positive Clinical Data from Prostate Cancer Study

(Date:10/7/2008)...RNewswire-FirstCall/ -- Stallergenes S.A.,today an...greement with,Catalent for the promotion and distr...FLEX(R), co-developed and co-manufactured by Catal...sts of a syringe pre-filled with adrenaline, which....3 and 0.15 mg), in an,autoinjector device. The Me...

(Date:10/7/2008)...of asthma in a young child may well be more challe..., according to a review of research and clinical e... Indiana University School of Medicine and Riley H... issue of Clinical Pediatrics . , "Wheezing ca... Professor of Pediatrics at the IU School of Medic...

(Date:10/7/2008)...rial Specialties, Mfg. is pleased to announce the ...hese filters are exclusively available from Indust... push-to-connect style fittings integrated into th...ne filter offers versatility and customization for... (PRWEB) October 7, 2008 -- Exclusively availa...

(Date:10/6/2008)...fight against childhood obesity, researcher notes ... Three-quarters of middle schools have vending mac...new study finds. , The research demonstrates th...ls, and "that those vending machines don,t always ...y Virus, a registered dietitian with the Center fo...

Breaking Medicine News(10 mins):Health News:Stallergenes Partners With Catalent and the Medical House for Commercialization of Adrenaline Autoinjector in Europe 2 Health News:Wheezing and asthma in young children 2 Health News:Vending Machines Found in Most Middle Schools 2

[0] Stallergenes Partners With Catalent and the Medical House for Commercialization of Adrenaline Autoinjector in Europe [0] Wheezing and asthma in young children [0] Push-to-Connect In-Line Filters Introduced [0] Vending Machines Found in Most Middle Schools

India, Pakistan Teams To Inaugurate Inzy's Hospital

... been found through an animal study that Aspartame...ut that drinking four to five 20-ounce bottles of ...be the //cause of cancers. The study would be pub...ironmental Health Perspectives, an US government-r...

...East Asia has been long considered a wonderland fo...otel lobbies or restaurants without any inhibition...vernment is seriously thinking about imposing a sm...bars. In Malaysia and Thailand, smoking bans alre...

...attempting to learn a new task, taking short break...easy, according to a new study conducted by Massac...d Foster and Matthew Wilson, working at the Massac...bridge, found that rats' brains 'replay' their exp...

Other Medicine News:Health News:Smoking Ban To Be Soon Implemented In South East Asian Bars 2 Health News:Task Learning Made Simple By Taking Short Breaks 2

India, Pakistan Teams To Inaugurate Inzy's Hospital Artificial sweetener, Aspartame, may be the potential cause of lymphoma, leukaemia Smoking Ban To Be Soon Implemented In South East Asian Bars Task Learning Made Simple By Taking Short Breaks

Lorenz 2.0 mm titanium system for the midface provides an excellent alternative to lower profile systems in areas of the midface where greater fixation is needed.

The Neuroclip is designed for safe, quick, and stable fixation of cranial bone flaps. Application is simple with minimal instrumentation. The Neuroclip can be applied to the cranial bone flap while t

Lorenz 1.0 mm titanium system provides a rigid fixation alternative for areas with high palpability and prominent bone formation. These areas include the frontal bone and the areas surrounding the or

1.0 mm Micro System. The Titanium Micro System is also useful in the practice of ENT, Neurosurgery and Handsurgery.

Medicine Products:

Lorenz 2.0 mm Mini-plate Titanium Neuroclip Cranial Flap Fixation System Lorenz 1.0 mm Titanium System 1.0 mm Micro System

Isis Highlights Robust Drug Portfolio for Diabetes and Obesity at ADA ...( - Oral presentation on the potent b...),Health